# Differential Prognostic Value of Residual Nodal Burden in Breast Cancer Subtypes

## TL;DR

This study shows that the amount of remaining cancer in lymph nodes after chemotherapy affects survival differently depending on the type of breast cancer.

## Contribution

The study reveals that residual nodal burden has a stronger prognostic impact in triple-negative breast cancer compared to other subtypes.

## Key findings

- ypN stage is the strongest predictor of mortality after adjusting for other factors.
- Triple-negative breast cancer shows a 64% difference in 5-year survival between ypN0 and ypN3 patients.
- ER+/HER2− subtype has the smallest survival difference with only a 25% difference in 5-year survival between ypN0 and ypN3 patients.

## Abstract

Residual cancer burden (RCB) index after neoadjuvant chemotherapy (NAC) is highly prognostic in patients with breast cancer (BC) but does not account for subtype or the precise impact of residual nodal burden (RNB). We aimed to precisely de ne the effect of RNB on survival by subtypes.

Adult women with non-metastatic BC diagnosed from 2006–2021 in the National Cancer Database (NCDB) who received NAC followed by surgery within 8 months were included. RNB was also evaluated as a predictor of mortality with multivariable logistic regression. Kaplan-Meier analyses were performed to compare overall survival.

51,917 patients were included. After adjustment, ypN stage was the strongest predictor of mortality, with an odds ratio (OR) of 2.24 (95% CI 2.08–2.41) for ypN1 vs ypN0 and increased with increasing nodal burden - ypN2 vs ypN0 OR 5.03, 95% CI 4.60–5.51 and ypN3 vs ypN0 OR 8.85, 95% CI 7.88–9.93. Stratification of survival curves with higher RNB is most pronounced for triple-negative breast cancer (TNBC) with an absolute difference of 64% in 5-year overall survival between ypN0 and ypN3 patients, and lowest for the ER+/HER2− subtype with a 25% absolute difference in 5-year OS between ypN0 and ypN3 patients. On interaction analysis, ypN status was a stronger predictor of mortality for the TNBC subtype compared to other subtypes.

RNB has a significantly different impact on survival by BC subtypes. Future study of optimal therapeutic strategies for patients with residual nodal disease after NAC should account for subtype specific differences in prognosis.